Maria Victoria García‐Ortiz

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer

Marta Toledano‐Fonseca, Icíar de la Fuente, María José Ortiz‐Morales, Pablo Cano-Ramírez et autres

BACKGROUND: Colorectal cancer is one of the most common and deadly malignancies worldwide. Traditionally, all colon tumours have been treated as a single entity, but growing evidence shows that tumour behaviour differs markedly according to tumour sidedness. Right-sided and left-sided tumours exhibit …

es, us (code pays fourni par la source)

NR3C1 , LAX1 , and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer

Pablo Cano‐Ramírez, Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Nerea M. Herrera‐Casanova et autres

ABSTRACT Pancreatic cancer remains highly lethal, largely due to late diagnosis and limited efficacy of treatments. Improving first‐line treatment selection and patient monitoring requires novel, non‐invasive biomarkers beyond carbohydrate antigen 19‐9 (CA19‐9) and imaging. This study investigates epigenetic biomarkers from liquid biopsy …

es (code pays fourni par la source)

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Álvaro Rodríguez-Lescure, Javier Gállego, Pilar García‐Alfonso, Bartomeu Massutí et autres

es (code pays fourni par la source)

Glycolysis Inhibition Restores Immune Sensitivity in GSNOR–Deficient Colorectal Cancer

Ana Mantrana, María Teresa Sánchez-Montero, Carmen Navarrete‐Sirvent, Nerea M. Herrera‐Casanova et autres

S-nitrosoglutathione reductase (GSNOR) is increasingly recognized as a tumor suppressor, and we have recently reported that its deficiency drives an aggressive and immune-evasive phenotype in colorectal cancer (CRC). However, the mechanisms linking GSNOR loss to immune escape remain incompletely understood. In this …

es, fr, us (code pays fourni par la source)

Circulating hsa‐miR‐29c‐3p and VEGF‐A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Elena Élez, Javier Soto‐Alsar et autres

BACKGROUND: Metastatic colorectal cancer (mCRC) patients who progress on oxaliplatin-based chemotherapy benefit from second-line treatment with FOLFIRI plus the antiangiogenic drug aflibercept. However, the absence of validated biomarkers for antiangiogenic therapies remains a challenge. In this context, we previously reported that combining …

es, us (code pays fourni par la source)

Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance

Marta Toledano‐Fonseca, Elena Brozos-Vázquez, Maria Victoria García‐Ortiz, Nicolás Costa‐Fraga et autres

Pancreatic cancer is usually diagnosed at advance stages leading to a poor prognosis and high mortality rates. Furthermore, only a small fraction of patients are elegible for surgery, which is the only curative treatment available. Obtaining tissue biopsies in pancreatic cancer is …

es, de (code pays fourni par la source)

Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement

Carmen Navarrete‐Sirvent, Ana Mantrana, Aurora Rivas‐Crespo, Alejandra Díaz‐Chacón et autres

Dear Editor,Antibody-dependent cell-mediated cytotoxicity (ADCC) induced by natural killer (NK) cells is one important mechanism by which the anti-EGFR cetuximab exerts its anti-tumoral effect, 1 but no studies have examined NK cell profiles as a predictor of response to cetuximab in metastatic …

es, fr (code pays fourni par la source)

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, Maria Victoria García‐Ortiz et autres

Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15-20% of patients are candidates, with a high risk of relapse. …

es, de (code pays fourni par la source)

Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects

Maria Victoria García‐Ortiz, Pablo Cano-Ramírez, Marta Toledano‐Fonseca, Enrique Aranda et autres

Pancreatic cancer is one of the most challenging cancers due to its high mortality rates. Considering the late diagnosis and the limited survival benefit with current treatment options, it becomes imperative to optimize early detection, prognosis and prediction of treatment response. To …

es, us (code pays fourni par la source)

Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy

Silvia Guil‐Luna, Aurora Rivas‐Crespo, Carmen Navarrete‐Sirvent, Ana Mantrana et autres

Glycogen synthase kinase 3 (GSK-3) has been proposed as a novel cancer target due to its regulating role in both tumor and immune cells. However, the connection between GSK-3 and immunoevasive contexture, including tumor budding (TB) has not been previously examined. Methods: …

es, ca (code pays fourni par la source)

Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Maria Victoria García‐Ortiz, Pablo Cano-Ramírez, Marta Toledano‐Fonseca, María Teresa Cano et autres

BACKGROUND: Pancreatic cancer is the most lethal cancer with a dismal prognosis mainly due to diagnosis at advanced stage and ineffective treatments. CA19-9 levels and computed tomography (CT) imaging are the main standard criteria for evaluating disease progression and treatment response. In …

es, us (code pays fourni par la source)

Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer

Rafael Mena‐Osuna, Ana Mantrana, Silvia Guil‐Luna, María Teresa Sánchez-Montero et autres

Abstract S‐nitrosoglutathione reductase (GSNOR) is a denitrosylase enzyme that has been suggested to play a tumor suppressor role, although the mechanisms responsible are still largely unclear. In this study, we show that GSNOR deficiency in tumors is associated with poor prognostic histopathological …

es (code pays fourni par la source)